Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics Inc (NQ: AKRO )

20.14 +0.22 (+1.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 577,856
Open 20.06
Bid (Size) 20.14 (2)
Ask (Size) 20.17 (9)
Prev. Close 19.92
Today's Range 19.82 - 20.35
52wk Range 11.25 - 58.38
Shares Outstanding 50,086,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
WHY: NEW YORK, NY - (NewMediaWire) - May 19, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal

Performance

YTD
-14.22%
-14.22%
1 Month
-2.99%
-2.99%
3 Month
-6.85%
-6.85%
6 Month
+20.82%
+20.82%
1 Year
-55.89%
-55.89%

More News

Read More
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lincoln, Compass Minerals, Exscientia, and Akero and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Abraham, Fruchter & Twersky LLP Notifies Shareholders of a Class Action Lawsuit on Behalf of Investors who Acquired Shares of Akero Therapeutics, Inc. (NYSE: AKRO)
From Abraham, Fruchter & Twersky, LLP
Via GlobeNewswire
Robbins LLP Reminds Investors of AKRO of the Pending Lead Plaintiff Deadline in the Akero Therapeutics, Inc. Class Action
From Robbins LLP
Via GlobeNewswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
ROSEN, A LEADING NATIONAL FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
ROSEN, A LEADING NATIONAL FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors with losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors with losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Kirby McInerney LLP Reminds Akero Therapeutics, Inc. (AKRO) Investors of Class Action Filing and Encourages Investors to Contact the Firm
From Kirby McInerney LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exscientia, Akero, Equinix, and Harbor Diversified and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
AKRO Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against Akero Therapeutics, Inc.
From Robbins LLP
Via Business Wire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)
From Glancy Prongay & Murray LLP
Via Business Wire
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.